InvestmentApr 24, 2026, 04:12 PM
Altimmune Raises $211.2M in Public Offering
AI Summary
Altimmune, Inc. completed a public offering, raising approximately $211.2 million in net proceeds. The offering included 64,250,000 shares of common stock and 10,750,000 pre-funded warrants, each accompanied by common stock warrants. The company plans to use the funds to advance the clinical development of pemvidutide, including its global pivotal Phase 3 trial for MASH, and for general corporate purposes.
Key Highlights
- Raised approximately $211.2 million in net proceeds.
- Issued 64,250,000 common shares at $3.00 per share.
- Issued 10,750,000 pre-funded warrants at $2.999 each.
- Funds to advance pemvidutide clinical development.